Protein– tag –
-
Clarivate Releases ‘Drugs to Watch in 2026’ List: AI Drug Discovery and DDS Technologies Highlighted as Promising Candidates
Clarivate UK Overview Clarivate released its mid-year 'Drugs to Watch' list for 2026, emphasizing that AI drug discovery and innovative drug delivery system (DDS) technologies are key trends driving the future market. The list includes A... -
AI Accelerates Drug Discovery from Years to Days, Transforming Molecular Design and Generative Chemistry
Uplatz (YouTube) Unknown Overview This video discusses how AI is transforming drug discovery by accelerating molecular design, protein structure prediction, and generative chemistry, enabling molecule design in days. However, it highligh... -
Lonza Offers Integrated ADC Clinical and Commercial Manufacturing Services, Covering Antibody to Sterile Fill-Finish
Lonza Switzerland Overview Lonza offers integrated development and manufacturing services for Antibody-Drug Conjugates (ADCs), encompassing antibodies, payloads, bioconjugation, and sterile fill and finish. The company operates GMP produ... -
RNAi Therapeutics Advance in Metabolic Disease Treatment with Liver-Targeted DDS and Emerging Self-Delivery siRNAs
ResearchGate (Trends in Pharmacological Sciences) Unknown Overview This article discusses RNA interference (RNAi) as a therapeutic strategy for metabolic diseases, emphasizing its advantage in targeting virtually all genes. Despite deliv... -
Chai Discovery Raises $400M in Series C, Valuation Reaches $3.8B, Announces Novartis Collaboration
AIPressRoom USA Overview Chai Discovery has raised $400 million in a Series C round, bringing the AI drug discovery company's valuation to $3.8 billion. The company, which uses generative AI to design new antibodies and proteins, announc... -
Nurix Therapeutics’ Bexobrutideg Shows 83% ORR and 22.1 Months PFS in Relapsed/Refractory CLL/SLL Phase 1 Study
Nurix Therapeutics USA Overview Nurix Therapeutics reported updated clinical data from its NX-5948-301 Phase 1a/1b study, showing durable responses and a favorable tolerability profile for bexobrutideg in relapsed/refractory CLL/SLL pati... -
Ractigen’s SOD1-ALS siRNA Therapy RAG-17 Shows Significant SOD1 Reduction and Favorable Safety in Phase 1, Published in Nature Medicine
BioSpace USA Overview Ractigen Therapeutics published preclinical and positive First-in-Human Phase 1 clinical data for RAG-17, an siRNA therapy for SOD1-ALS, in Nature Medicine. The trial met primary safety endpoints with no serious adv... -
Isomorphic Labs’ AlphaFold 3-Designed AI Drug Candidates Enter First-in-Human Clinical Trials for Solid Tumors
IntuitionLabs USA Overview Isomorphic Labs, a Google DeepMind spin-off, has initiated first-in-human clinical trials for oncology candidates designed using AlphaFold 3 and proprietary AI models. This landmark achievement signifies one of... -
UT Southwestern Develops Biosensor to Track Alpha-Ketoglutarate for Childhood Brain Disorder GPT2 Deficiency
UT Southwestern, Dallas, Texas USA Overview Scientists at UT Southwestern's Children's Medical Center Research Institute have developed a novel biosensor to track alpha-ketoglutarate (αKG), a vital metabolite, to better understand GPT2 d... -
Creative Biolabs Integrates Microfluidics and Electrochemical Biosensors to Accelerate Next-Generation POCT Diagnostics
24-7 Press Release USA Overview Creative Biolabs has announced a new platform integrating microfluidics and electrochemical biosensors, aiming to accelerate next-generation Point-of-Care Testing (POCT) diagnostics. This combination achie...
